TLR9 and melanoma: Neoadjuvant intralesional therapy for melanoma has been studied in 2 phase II trials using talimogene laherparepvec (T-VEC) and ‘CheckMate Pharmaceuticals’©, toll-like receptor 9 agonist (CMP-001).